Current
Research in
Ophthalmology >>

Safety, Pharmacokinetics, Immunogenicity, and Clinical Response to Multiple Subcutaneous Administrations of the Human Monoclonal Antibody to Human TNF-alpha (CNTO 148) in Patients with Intermediate Uveitis, Poster Uveitis, or Panuveitis

Principal Investigator

C. Michael Samson, M.D.

Enrollment Status  

Completed

Objective 

To evaluate the safety of multiple subcutaneous (SC) administrations of CNTO 148 at 3 dose levels compared with placebo in subjects with intermediate uveitis, posterior uveitis, or panuveitis.  This is a Phase I/IIA, double-masked, placebo-controlled, multicenter study.

Eligibility

Patients with intermediate uveitis, posterior uveitis, or panuveitis and disease control dependent upon a minimum dose of 0.13 mg/kg/day or 10 mg/day of systemic prednisone or equivalent, whichever is less. Patients with vitreous haze no greater than 1+ will be considered.

Study results are currently being analyzed. Please visit this webpage next month for the study update. For more information: ClinicalTrials.gov

Home > Current Research > Clinical Trials in Ophthalmology > Results > Safety, Pharmacokinetics, Immunogenicity, and Clinical Response to Multiple Subcutaneous Administrations of the Human Monoclonal Antibody to Human TNF-alpha (CNTO 148) in Patients with Intermediate Uveitis, Poster Uveitis, or Panuveitis